Fresenius Medical Care Ventures, the venture capital unit of Fresenius Medical Care, announced today that it has invested $2 million in the Series B financing round for Vectorious Medical Technologies.
Fresenius Medical Care today successfully placed notes with an aggregate principal amount of €500 million.
Fresenius Medical Care today announced the closing of the divestiture of Sound Inpatient Physicians Holdings, LLC (Sound) to an investment consortium led by Summit Partners as of June 28, 2018
Revenue in the first quarter 2018 was significantly impacted by a 12% negative impact resulting from foreign currency translation, declining 1% at constant currency to EUR 3,976 million.
Press Release Fresenius Medical Care, the world’s largest provider of dialysis products and services, today announced a leadership change in its EMEA (Europe, Middle East and Africa) region....
Fresenius Medical Care, the world’s largest provider of dialysis products and services, has decided to adjust its 2018 revenue growth target from around 8 percent to a range of 5 to 7 percent at...
The addition of Parsabiv as an injectable calcimimetic drug in the U.S. triggered the move of the corresponding reimbursement for Medicare patients from Part D to Part B.